INTRODUCTION
M ONOAMINE TRANSPORTERS are presynaptic membrane proteins that regulate neurotransmission by rapidly removing the neurotransmitters norepinephrine, dopamine, and serotonin from the synaptic cleft. 1 Monamine transporter inhibitors block reuptake of these neurotransmitters, thereby elevating extracellular levels and prolonging signaling. Selective inhibitors of the human norepinephrine transporter (NET) have shown clinical utility in the treatment of major depressive disorder and attention deficit disorder. 2, 3 Unlike older-generation tricyclic antidepressants, which exhibit poor receptor selectivity, the norepinephrine selective reuptake inhibitors exhibit a more favorable side effect profile, including reduced cardiovascular, anticholinergic, and sedative liabilities.
Although there is a long history of drug discovery focused around the monoamine transporters, screening for selective inhibitors has been hampered by the absence of robust and highthroughput functional assays. Radiolabeled substrate uptake assays are cumbersome, requiring multiple wash steps, and are not amenable to higher density formats such as 384-and 1536well plates. Consequently, most screens reported for transport inhibitors use radioligand binding assays followed by uptake assays to assess functional inhibition. This approach is likely to bias the screen toward compounds that occupy the same binding site and therefore the same chemical space as the radioligand used in the screen. A recently identified fluorescent substrate, 4-(4dimethylaminostyryl)-N-methylpyridinium (ASP + ), for NET has opened the possibility of screening for functional NET inhibitors in a truly high-throughput format. 4, 5 To this end, we have developed a functional assay for NET inhibitors on the FLIPR Tetra (Molecular Devices, Sunnyvale, CA) using ASP + and show that it is sufficiently robust and miniaturizable for high-throughput screening (HTS) in either kinetic or end-point reading modes.
MATERIALS AND METHODS

Cell culture
HEK293 cells stably expressing human NET were cultured in growth medium containing Dulbecco's Modified Eagle's Medium (DMEM) supplemented with 4.5 g/L glucose and 1 mM sodium pyruvate (Mediatech, Inc., Herndon, VA), 10% heat-inactivated dialyzed fetal bovine serum (FBS; HyClone, Logan, UT), 2 mM L-glutamine, 10 mM HEPES, 50 µg/mL penicillin-streptomycin, and 250 µg/mL G418 (Mediatech). 
Fluorescent NET transport assays and HTS on the FLIPR Tetra
On the day prior to the assay, cells were removed from culture flasks using enzyme-free cell dissociation buffer (Mediatech) and plated in growth medium at 8000 to 20,000 cells per well into black, clear-bottom, 384-square-well poly-D-lysine (Sigma-Aldrich, St. Louis, MO)-coated plates (Corning, Inc., Corning, NY) using a Multidrop dispenser (Thermo, Waltham, MA). On the day of the assay, growth medium was removed using the ELx405 platewasher (BioTek, Winooski, VT) with 2 washes of 90 µL transport buffer (122 mM NaCl, 3 mM KCl, 1.3 mM CaCl 2 , 1.2 mM KH 2 PO 4 , 0.4 mM MgSO 4 , 20 mM HEPES), leaving 20 µL residual in each well. Subsequently, 20 µL transport buffer containing 700 µM trypan blue (Sigma-Aldrich) was added to each well. An additional 10 µL of 7× inhibitor or test compound in transport buffer plus 700 µM trypan blue was then added to each well and incubated at room temperature (RT) for 20 min. The assay plate was then placed inside the FLIPR Tetra (Molecular Devices) along with a plate containing 42 µM ASP + (Invitrogen, Carlsbad, CA) substrate in transport buffer plus trypan blue. The FLIPR Tetra on-board liquid handler was used to simultaneously begin reading and adding 20 µL of the ASP + substrate to each well of the assay plate. Final assay concentrations were 12 µM and 500 µM for ASP + and trypan blue, respectively. A read was taken every 2 s for 600 s (excitation = 470-495, emission = 565-625). For endpoint reads, the plates were read for 3 exposures at 2-s intervals, and the relative fluorescence units (RFUs) were averaged.
Radiolabeled substrate uptake assays
HEK293 cells expressing human NET were seeded at 15,000 cells/well in 50 µL of tissue culture medium (DMEM; 4.5 g/L glucose; 1 mM sodium pyruvate; 10% heat-inactivated, dialyzed FBS; 2 mM L-glutamine; 10 mM HEPES; 50 µg/mL penicillinstreptomycin; 250 µg/mL G418) into 384-well, white, tissue culture-treated plates (Corning, Inc.) precoated with poly-Dlysine and collagen (BD Biosciences, La Jolla, CA). Following a 24-h incubation, the media were gently aspirated from each well and the plates washed twice on an ELx405 plate washer (BioTek) with 75 µL of transport buffer supplemented with 1 mM ascorbic acid (reducing agent), 0.1 mM pargyline (monoamine oxidase inhibitor), and 0.1 mM tropolone (catechol-O-methyltransferase inhibitor) to prevent degradation of monoamine substrates. To each well was added 50 µL of transport buffer followed by 25 µL of test compound prediluted at 4× the final assay concentration in transport buffer containing 2% DMSO. Plates were then incubated for 20 min at RT. Subsequently, 25 µL of levo-[ring-2,5,6-3 H]-norepinephrine (PerkinElmer, Wellesley, MA; 186 nM) prediluted in transport buffer was added to each well, bringing the final assay concentration to 46 nM, or about 700-fold below the Km (data not shown). Plates were incubated at RT for 20 min, after which the buffer was aspirated from each well and the plate washed twice with 4 °C wash buffer (280 mM D-mannitol [to maintain osmotic balance in the absence of NaCl], 5.4 mM KCl, 1.8 mM CaCl 2 , 0.8 mM MgSO 4 , 20 mM HEPES, 1 mM ascorbic acid, 0.1 mM pargyline, 0.1 mM tropolone). Cells were then lysed by the addition of 5 µL 5% SDS followed by a 30-min incubation at RT. Following lysis, 80 µL of Microscint-20 (PerkinElmer) was added to each well and the assay plates shaken for 4 h at RT before reading on a TopCount (PerkinElmer) to quantify radioactivity. The standard control for the assay was desipramine, which was run on each plate in quadruplicate in a 12-point dose response, with a highest test concentration of 1 µM.
Radiolabeled ligand binding assays
Test compounds were serially diluted in assay buffer (120 mM NaCl, 5 mM KCl, 25 mM HEPES, pH 7.4) in 96-well, white, non-binding-surface-treated plates (Corning, Inc.) and then transferred in duplicate (20 µL) to 384-well, white, nonbinding surface-treated plates. Subsequently, 30 µL of [ 3 H]nisoxetine in assay buffer was added to a final assay concentration of 3 nM. The competition binding reaction was initiated by the addition of 30 µL of membranes prepared from NET-transfected HEK293 cells. Assay plates were incubated at RT for 2 h and the reaction terminated by rapid vacuum filtration onto 384-well GF/C filter plates (Millipore, Billerica, MA) that had been pretreated with 1% polyethylenimine at 4 °C and washed 4 times with 95 µL of ice-cold assay buffer. After filtration, the filter plates were washed 3 times with 95 µL of cold wash buffer (154 mM NaCl, 25 mM HEPES, 0.01% Triton X-100, pH 7.4) and dried, and 14 µL of Microscint-20 (Packard, Wellesley, MA) was added to each well. Radioactivity was measured using a TopCount NXT (PerkinElmer).
RESULTS AND DISCUSSION
Recently, Mason and others described the use of a fluorescent substrate, ASP + , for kinetic monoamine transporter uptake assays using a FlexStation™ (Molecular Devices). 5 Because the kinetics of the transporter uptake assay are slow and read times are long (∼500 s) compared to G protein-coupled receptors (∼30 s), the fluorescent uptake assay run on the FlexStation™ may be suitable for small-scale structure-activity relationship experiments; however, the assay as described by Mason and others is excluded for HTS by the 96-well format and the limitation of the instrument to reading only 8 wells at a time. We therefore sought to develop an assay that would be amenable to true HTS of >20,000 compounds per day.
The FLIPR Tetra from Molecular Devices has eliminated the high-intensity laser found on older models and instead uses 2 banks of light-emitting diodes (LEDs) to illuminate the bottom of the plate containing the cells. The data from the entire plate are recorded by a cooled CCD camera, and on-board liquid handling from a 96-or 384-well head allows simultaneous liquid addition and kinetic reading of 96-, 384-, and 1536-well plates. The availability of the 2 LED banks allows dual wavelengths to be assessed during the assay for ratiometric reads. Importantly, the excitation wavelength of the ASP + substrate (475 nm) falls within the FLIPR Tetra Fluo-4 calcium dye excitation optics range of 470 to 495 nm, and the emission wavelength of ASP + (609 nm) falls within the range of the optional emission optics of 565 to 625 nm for the membrane potential dye. By adjusting the settings on the FLIPR Tetra to excite with the calcium optics and read with the available membrane potential optics, we were able to obtain a robust signal corresponding to the specific uptake of the ASP + dye into NET-expressing cells.
Initial experiments centered on optimization of the assay for 384-well miniaturization. Cells were plated the day prior to the assay in Costar poly-D-lysine-coated 384-well black, clearbottom plates at 8000 to 20,000 cells per well. After washing and ASP + dye addition in the FLIPR Tetra , the plates were read at 2-s intervals for up to 1000 s. Wells containing cells, ASP + , and the NET inhibitor desipramine served as controls. All subsequent experiments were carried out with 15,000 cells per well. Initial experiments showed reduced uptake kinetics in the perimeter wells of the 384-well plate. Follow-up studies demonstrated that this edge effect was due to differential cooling of the plate over time (data not shown) and was consistent with reports in the literature of temperature sensitivity for transporter activity. This phenomenon was eliminated by allowing the plates and all reagents to equilibrate to RT prior to the assay. All subsequent experiments were conducted with RT reagents. We then conducted matrix experiments to determine the optimal trypan blue to ASP + ratio to determine the maximal signal window. In the 384-well assay, we were able to achieve a signal-to-background ratio of approximately 6-fold (versus control wells containing 1 µM desipramine) using 12 µM ASP + and quenching with 500 µM trypan blue. Optimization of liquid-handling and plate-washing steps resulted in Z′ scores in excess of 0.6 with very little variability (Fig. 1A, B) . The Km determined for ASP + uptake in the 384-well FLIPR Tetra assay (3.5 ± 0.3 µM) was similar to that reported previously (2.1 µM) using the FlexStation assay (Fig. 1C) . 5 To assess how the assay would perform under true highthroughput conditions, we performed a miniscreen of 30 randomly selected 384-well plates from the NBI compound library, with each plate containing 336 compounds, for a total of approximately 10,000 compounds. In addition, the known NET antagonist desipramine was spiked into the compound plates in 6 random locations at a final assay concentration of 1 µM to validate the robustness of the assay. addition in the FLIPR Tetra . ASP + accumulation was allowed to proceed for 600 s, with a reading taken every 2 s. Specific ASP + accumulation after 600 s was determined by subtracting final RFU values in the presence of desipramine from final RFU values in the absence of desipramine. To test whether a shorter data collection window could be used to reduce FLIPR Tetra instrument time, we also measured specific ASP + accumulation for a 6-s reading on the FLIPR Tetra taken at the end of a 600-s off-line accumulation period. In both the 6-s and 10-min reading modes, Z′ scores were above the standard acceptable level of 0.5 for all plates tested, with average values of 0.612 ± 0.013 and 0.627 ± 0.014 (mean ± SEM) for the 6-s and 10-min reading formats, respectively. In addition, the desipramine-spiked wells were correctly identified 100% of the time in both cases. Raw screening data for the 6-s reading format are shown in Figure 2A , and the statistics (distribution) of hits are shown in Figure 2B . Compounds ≥3 SD from the mean were identified as hits. Screening hits were highly concordant between the 2 reading modes, with 273 of 284 (96.2%) hits identified in the 10-min reading format also identified in the 6-s reading format.
In the 6-s reading mode, with a robotic plate processing time of 2 min into and out of the FLIPR, we estimate that a throughput of 360 plates per day can be achieved, assuming a 12-h screening day. With 336 compounds per 384-well plate, this equals approximately a 120,000 compound per day throughput. To test the reproducibility and robustness of the screening assay, the 284 compounds identified as hits in the primary screen (≥3 SD from the mean) were retested in duplicate using the 10-min reading conditions. After analysis, 184 compounds, or 65%, were confirmed as actives, inhibiting ASP + uptake by more than 66% at 10 µM. Analysis of the 184 structures revealed that clomipramine, a commercially available NET inhibitor, was present in the randomly selected screening plates . (B) Data from the 6-s end point read were analyzed using Spotfire and hits selected as those compounds with inhibition ≥3 SD from the mean (>66% inhibition; 2.8% of compounds tested). Average Z′ scores were 0.63 and 0.61 for the kinetic and end-point reads, respectively. Of the 30 plates tested, no Z′ score was less than 0.5. and was also identified from the screen. Clomipramine and 3 other known NET inhibitors were tested in full dose responses in the ASP + kinetic uptake assay, the [ 3 H]-norepinephrine uptake assay, and the NET binding assay. As shown in Figure  3 and Figure 4 , the kinetic ASP + uptake assay yielded doseresponse data on the FLIPR Tetra with a very good correlation between the rank order of potency in the binding and [ 3 H]norepinephrine uptake assays for the 4 known inhibitors spanning a range of activity.
In conclusion, we have expanded on the recent publication from Mason and others 5 to develop a functional 384-well NET uptake assay capable of robotic integration and full-scale highthroughput screening. This assay has the capacity to screen more than 120,000 compounds per day and should greatly speed the drug discovery process for NET inhibitors, including potentially novel lead series, which interact with sites on NET that are distinct from existing antagonist ligands discovered via radioligand binding assay.
